Skip to content

XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects

XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects. Despite these side effects, the company added that both 800 mg and 400 mg doses of the drug given to patients in Phase 2 clinical trial helped to alleviate psoriasis. XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects. Latest stock quote data for XNPT (XenoPort Inc) from Stockpickr.com.

XenoPort (XNPT) Stock Plunged After Psoriasis Drug's Negative Side Effects 2XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects. XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects Read the original story w/Photo. 6 hrs ago TheStreet.com. XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects.

Thus far today, XenoPort has traded 2.8 million shares, vs. average volume of 2. (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects. XenoPort, Inc. to Post Q1 2016 Earnings of (0.26) Per Share, Jefferies. XenoPort (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects.

Xenoport, Nasdaq:xnpt Market News

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2015 Credit Suisse Healthcare Conference in Phoenix, Arizona. (XNPT) Stock Plunged After Psoriasis Drug’s Negative Side Effects. XenoPort XNPT fell 28 after investors’ initial positive take on clinical trials results for an experimental psoriasis drug turned negative. But now the stock has reversed course, plunged almost 12.8 to a recent 6.73. XenoPort (XNPT) was soaring in pre-market action, jumping as much as 16 after it released positive top line preliminary results from a mid-stage study testing its experimental psoriasis medication XP23829. Detailing the side effects of this drug, though, investigators noted 22 to 40 of the patients in the drug arms suffered from diarrhea. In this environment, weak stocks make good shorts, and one of the most vulnerable is XenoPort (Nasdaq: XNPT). XenoPort (XNPT) shares rose in midday trading after the company was rumored to have emerged as a buyout target for Supernus Pharmaceuticals (SUPN). Though the firm believes substantially lesser gastrointestinal side effects could be enough to threaten Biogen’s market share in multiple sclerosis. After meeting with a psoriasis doctor, RBC says that the company’s ‘829 drug could be superior to Celgene’s (CELG) Otezla as a treatment for psoriasis and potentially MS. Stocks turn negative in afternoon trading. Psoriasis Forums – Articles, reviews, news and resources related to Psoriasis.

Xenoport (xnpt) Stock Plunged After Psoriasis Drug’s Negative Side Effects

XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D disappointments. Things went awry for XenoPort last year when XP23829, an oral psoriasis drug, came through with mixed results in a Phase II study. ‘Brexit’ risks serious side effects for U.K. life sciences. Shares of Exact Sciences (NASDAQ: EXAS) plunged after the U.S.